Phosphate Frustration: Treatment Options to Complement Current Therapies
Hyperphosphatemia eventually develops in almost all patients with advanced chronic kidney disease and is associated with negative clinical outcomes. Thus, guidelines recommend targeting treatment to normal phosphate levels in patients with chronic kidney disease. Despite low phosphorus diets, cleara...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2022/9457440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553028123623424 |
|---|---|
| author | Pablo E. Pergola |
| author_facet | Pablo E. Pergola |
| author_sort | Pablo E. Pergola |
| collection | DOAJ |
| description | Hyperphosphatemia eventually develops in almost all patients with advanced chronic kidney disease and is associated with negative clinical outcomes. Thus, guidelines recommend targeting treatment to normal phosphate levels in patients with chronic kidney disease. Despite low phosphorus diets, clearance by dialysis, and phosphate binder use, many patients with chronic kidney disease on dialysis are unable to consistently achieve and maintain serum phosphate concentrations <5.5 mg/dL. A chart audit of patients on dialysis receiving phosphate binders showed that 74 to 86% were unable to consistently achieve serum phosphate ≤5.5 mg/dL over 6 months. Furthermore, although there is evidence that serum phosphate concentrations <4.5 mg/dL are associated with improved survival and cardiovascular outcomes, real-world phosphate control data suggest achieving and maintaining this goal for most patients would be extremely challenging, if not near impossible, using current therapies. As phosphate binders can only remove approximately 300 mg of the 2,500 mg or more daily dietary phosphate intake, therapeutic innovations are necessary to improve phosphate management. We present treatment options to complement current therapies including tenapanor, a novel sodium/hydrogen exchanger isoform 3 inhibitor that blocks the dominant paracellular phosphate absorption pathway and has been shown to reduce phosphate levels in several clinical trials. |
| format | Article |
| id | doaj-art-ffe152e138be404e8b76d23b0e2393ec |
| institution | Kabale University |
| issn | 2090-2158 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-ffe152e138be404e8b76d23b0e2393ec2025-02-03T05:57:23ZengWileyInternational Journal of Nephrology2090-21582022-01-01202210.1155/2022/9457440Phosphate Frustration: Treatment Options to Complement Current TherapiesPablo E. Pergola0Renal AssociatesHyperphosphatemia eventually develops in almost all patients with advanced chronic kidney disease and is associated with negative clinical outcomes. Thus, guidelines recommend targeting treatment to normal phosphate levels in patients with chronic kidney disease. Despite low phosphorus diets, clearance by dialysis, and phosphate binder use, many patients with chronic kidney disease on dialysis are unable to consistently achieve and maintain serum phosphate concentrations <5.5 mg/dL. A chart audit of patients on dialysis receiving phosphate binders showed that 74 to 86% were unable to consistently achieve serum phosphate ≤5.5 mg/dL over 6 months. Furthermore, although there is evidence that serum phosphate concentrations <4.5 mg/dL are associated with improved survival and cardiovascular outcomes, real-world phosphate control data suggest achieving and maintaining this goal for most patients would be extremely challenging, if not near impossible, using current therapies. As phosphate binders can only remove approximately 300 mg of the 2,500 mg or more daily dietary phosphate intake, therapeutic innovations are necessary to improve phosphate management. We present treatment options to complement current therapies including tenapanor, a novel sodium/hydrogen exchanger isoform 3 inhibitor that blocks the dominant paracellular phosphate absorption pathway and has been shown to reduce phosphate levels in several clinical trials.http://dx.doi.org/10.1155/2022/9457440 |
| spellingShingle | Pablo E. Pergola Phosphate Frustration: Treatment Options to Complement Current Therapies International Journal of Nephrology |
| title | Phosphate Frustration: Treatment Options to Complement Current Therapies |
| title_full | Phosphate Frustration: Treatment Options to Complement Current Therapies |
| title_fullStr | Phosphate Frustration: Treatment Options to Complement Current Therapies |
| title_full_unstemmed | Phosphate Frustration: Treatment Options to Complement Current Therapies |
| title_short | Phosphate Frustration: Treatment Options to Complement Current Therapies |
| title_sort | phosphate frustration treatment options to complement current therapies |
| url | http://dx.doi.org/10.1155/2022/9457440 |
| work_keys_str_mv | AT pabloepergola phosphatefrustrationtreatmentoptionstocomplementcurrenttherapies |